Kera Capital Partners Inc. Invests $288,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kera Capital Partners Inc. bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 2,336 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000.

A number of other large investors have also recently made changes to their positions in JAZZ. Itau Unibanco Holding S.A. acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC boosted its stake in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares during the period. Finally, Versant Capital Management Inc raised its position in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after acquiring an additional 350 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Down 1.2 %

JAZZ opened at $121.18 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a fifty day simple moving average of $122.78 and a 200-day simple moving average of $114.67. The firm has a market cap of $7.33 billion, a P/E ratio of 17.07, a P/E/G ratio of 0.88 and a beta of 0.56.

Analysts Set New Price Targets

A number of brokerages have recently commented on JAZZ. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler restated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,253 shares of company stock valued at $1,001,434. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.